Sodium selenite as prophylaxis against erysipelas in secondary lymphedema
Identifieur interne : 00B657 ( Main/Exploration ); précédent : 00B656; suivant : 00B658Sodium selenite as prophylaxis against erysipelas in secondary lymphedema
Auteurs : R. Kasseroller [Autriche]Source :
- Anticancer research [ 0250-7005 ] ; 1998.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000A73
- to stream PascalFrancis, to step Curation: 001035
- to stream PascalFrancis, to step Checkpoint: 000A51
- to stream Main, to step Merge: 00BD75
- to stream Main, to step Curation: 00B657
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Sodium selenite as prophylaxis against erysipelas in secondary lymphedema</title><author><name sortKey="Kasseroller, R" sort="Kasseroller, R" uniqKey="Kasseroller R" first="R." last="Kasseroller">R. Kasseroller</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Wittlinger's Therapy Center, Alleestrasse 30</s1><s2>6344 Walchsee</s2><s3>AUT</s3><sZ>1 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>6344 Walchsee</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">98-0480585</idno><date when="1998">1998</date><idno type="stanalyst">PASCAL 98-0480585 INIST</idno><idno type="RBID">Pascal:98-0480585</idno><idno type="wicri:Area/PascalFrancis/Corpus">000A73</idno><idno type="wicri:Area/PascalFrancis/Curation">001035</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000A51</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000A51</idno><idno type="wicri:doubleKey">0250-7005:1998:Kasseroller R:sodium:selenite:as</idno><idno type="wicri:Area/Main/Merge">00BD75</idno><idno type="wicri:Area/Main/Curation">00B657</idno><idno type="wicri:Area/Main/Exploration">00B657</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Sodium selenite as prophylaxis against erysipelas in secondary lymphedema</title><author><name sortKey="Kasseroller, R" sort="Kasseroller, R" uniqKey="Kasseroller R" first="R." last="Kasseroller">R. Kasseroller</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Wittlinger's Therapy Center, Alleestrasse 30</s1><s2>6344 Walchsee</s2><s3>AUT</s3><sZ>1 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>6344 Walchsee</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Anticancer research</title><title level="j" type="abbreviated">Anticancer res.</title><idno type="ISSN">0250-7005</idno><imprint><date when="1998">1998</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Anticancer research</title><title level="j" type="abbreviated">Anticancer res.</title><idno type="ISSN">0250-7005</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiinflammatory agent</term><term>Clinical trial</term><term>Cohort study</term><term>Complication</term><term>Double blind study</term><term>Erysipelas</term><term>Human</term><term>Local administration</term><term>Lymphedema</term><term>Malignant tumor</term><term>Mammary gland</term><term>Prevention</term><term>Randomization</term><term>Selenium</term><term>Sodium Selenites</term><term>Surgery</term><term>Topical administration</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term><term>Complication</term><term>Chirurgie</term><term>Tumeur maligne</term><term>Glande mammaire</term><term>Homme</term><term>Sodium Sélénite</term><term>Voie externe</term><term>Voie locale</term><term>Etude cohorte</term><term>Sélénium</term><term>Erysipèle</term><term>Prévention</term><term>Randomisation</term><term>Etude double insu</term><term>Essai clinique</term><term>Antiinflammatoire</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chirurgie</term><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a randomised, double-blind study, the efficacy of sodium selenite application in combination with physical therapy to relieve congestion was investigated in a cohort of 60 cancer patients with secondary lymph edema, with special reference to the development of the incidence of erysipelas. All of the patients investigated in this study had erysipelas infection of the skin. Selenium was administered in pharmacological doses. The duration of physical therapy was three weeks. Patients were under observation for a further three months. The incidence of erysipelas among our patients was 11%. During the three-week period of intensive treatment, there was not a single case of erysipelas in the treatment group, whereas there was one single case in the placebo group. In the follow-up period (3 months), once again there was not a single case of erysipelas in the treatment group, but 50% of the patients in the placebo group exhibited erysipelas. In spite of higher doses, the selenium level did not rise above normal values. Patients under long-term antibiotic therapy suffered no relapse when the antibiotic therapy was stopped and instead, selenium was administered. It could be shown, in addition, that by administration of a single high-dose of sodium selenite, inflammation could be immediately brought under control.</div></front></TEI><affiliations><list><country><li>Autriche</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Kasseroller, R" sort="Kasseroller, R" uniqKey="Kasseroller R" first="R." last="Kasseroller">R. Kasseroller</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B657 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00B657 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:98-0480585
|texte= Sodium selenite as prophylaxis against erysipelas in secondary lymphedema
}}
| This area was generated with Dilib version V0.6.31. |  |